Guru Subramanian Guru Murthy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Guru Subramanian Guru Murthy has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Aniko Szabo
Department of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin
2 shared publicationsEhab Atallah
Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
2 shared publicationsPaulette Mehta
C Division of Hematology/Oncology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Health System , Little Rock , AR , USA
2 shared publicationsRaji Venkitachalam
B Cochin Medical College , Kochi , India
2 shared publications- Ajay Duseja
Department of Hepatology, PGIMER, Chandigarh, India
1 shared publication Alex Hinman
Clinical Trials Office, Medical College of Wisconsin, Milwaukee, Wisconsin
1 shared publication
Latest Publications
- Open Access
- 4 April 2024
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 109 (9) , 2864-2872
A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed acute myeloid leukemia (AML). However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL1 is suggested to be a potential resistance mechanism. Pevonedistat inhibits MCL1 through activation of NOXA, and pevonedistat/azacitidine has previously shown activity in AML. To assess the tolerability and efficacy of adding pevonedistat to azacitidine/ venetoclax in relapsed/refractory AML, we conducted a phase I, multicenter, open-label study in 16 adults with relapsed/ refractory AML. Patients were treated with azacitidine, venetoclax along with pevonedistat intravenously on days 1, 3 and 5 of each 28-day cycle at doses of 10, 15 or 20 mg/m2 in successive cohorts in the dose escalation phase. The impact of treatment on protein neddylation as well as expression of pro-apoptotic BCL2 family members was assessed. The recommended phase II dose of pevonedistat was 20 mg/m2. Grade 3 or higher adverse events included neutropenia (31%), thrombocytopenia (13%), febrile neutropenia (19%), anemia (19%), hypertension (19%) and sepsis (19%). The overall response rate was 46.7% for the whole cohort including complete remission in five of seven (71.4%) patients who had not previously been treated with the hypomethylating agent/venetoclax. No measurable residual disease was detected in 80.0% of the patients who achieved complete remission. The median time to best response was 50 (range, 23-77) days. Four patients were bridged to allogeneic stem cell transplantation. The combination of azacitidine, venetoclax and pevonedistat is safe and shows encouraging preliminary activity in patients with relapsed/refractory AML. (NCT04172844).
- 4 April 2024
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 109 (9) , 2864-2872
Open AccessA phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed acute myeloid leukemia (AML). However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL1 is suggested to be a potential resistance mechanism. Pevonedistat inhibits MCL1 through activation of NOXA, and pevonedistat/azacitidine has previously shown activity in AML. To assess the tolerability and efficacy of adding pevonedistat to azacitidine/ venetoclax in relapsed/refractory AML, we conducted a phase I, multicenter, open-label study in 16 adults with relapsed/ refractory AML. Patients were treated with azacitidine, venetoclax along with pevonedistat intravenously on days 1, 3 and 5 of each 28-day cycle at doses of 10, 15 or 20 mg/m2 in successive cohorts in the dose escalation phase. The impact of treatment on protein neddylation as well as expression of pro-apoptotic BCL2 family members was assessed. The recommended phase II dose of pevonedistat was 20 mg/m2. Grade 3 or higher adverse events included neutropenia (31%), thrombocytopenia (13%), febrile neutropenia (19%), anemia (19%), hypertension (19%) and sepsis (19%). The overall response rate was 46.7% for the whole cohort including complete remission in five of seven (71.4%) patients who had not previously been treated with the hypomethylating agent/venetoclax. No measurable residual disease was detected in 80.0% of the patients who achieved complete remission. The median time to best response was 50 (range, 23-77) days. Four patients were bridged to allogeneic stem cell transplantation. The combination of azacitidine, venetoclax and pevonedistat is safe and shows encouraging preliminary activity in patients with relapsed/refractory AML. (NCT04172844).
- 22 March 2024
- Published by Elsevier in Leukemia Research
- Vol. 140, 107496
Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry
- 22 March 2024
- Published by Elsevier in Leukemia Research
- Vol. 140, 107496
Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry
- 21 January 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (8) , 2296-2300
Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database
B-lineage acute lymphoblastic leukemia (B-ALL) in the elderly population is generally considered to have a poor prognosis. It is unclear whether their survival has improved in the current era. Using the Surveillance, Epidemiology, and End Results database, we selected 717 elderly patients (age ≥ 60) with B-ALL diagnosed between 1992 and 2011. Overall survival (OS) was compared based on their period of diagnosis and age. Patients in the age group 60–69 had an improvement in OS over time, both 1-year OS (49.4% in 2002–2011 vs. 33.1% in 1992–2001) and 5-year OS (20.4% in 2002–2011 vs. 8.1% in 1992–2001, p = 0.002). Patients ≥ 70 years had no significant improvement in 1-year OS or 5-year OS (5-year OS 5.5% in 1992–2001 vs. 9.7% in 2002–2011, p = 0.326). Hence, there are discrepancies in the improvement of OS among elderly patients with B-ALL. Further focus of research in elderly patients with B-ALL is needed to improve their outcome.
- 21 January 2015
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (8) , 2296-2300
Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database
B-lineage acute lymphoblastic leukemia (B-ALL) in the elderly population is generally considered to have a poor prognosis. It is unclear whether their survival has improved in the current era. Using the Surveillance, Epidemiology, and End Results database, we selected 717 elderly patients (age ≥ 60) with B-ALL diagnosed between 1992 and 2011. Overall survival (OS) was compared based on their period of diagnosis and age. Patients in the age group 60–69 had an improvement in OS over time, both 1-year OS (49.4% in 2002–2011 vs. 33.1% in 1992–2001) and 5-year OS (20.4% in 2002–2011 vs. 8.1% in 1992–2001, p = 0.002). Patients ≥ 70 years had no significant improvement in 1-year OS or 5-year OS (5-year OS 5.5% in 1992–2001 vs. 9.7% in 2002–2011, p = 0.326). Hence, there are discrepancies in the improvement of OS among elderly patients with B-ALL. Further focus of research in elderly patients with B-ALL is needed to improve their outcome.
- 8 June 2012
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 57 (11) , 3035-3037
Alagille Syndrome: A Rare Disease in an Adolescent
- 8 June 2012
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 57 (11) , 3035-3037
Alagille Syndrome: A Rare Disease in an Adolescent